Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 1/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 6/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.38 |
| ▸ | HTR7 | P34969 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.35 |
| ▸ | KIT | P10721 | 1/20 | 0.35 |
| ▸ | ACP1 | P24666 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7549559 | 0.89 | CCR2 (0.62) | CCR2HRH3AURKAACHEACP1 | |
| SCHEMBL7160102 | 0.86 | CCR2 (0.52) | CCR2HRH3ACHEADORA2AADORA1 | |
| SCHEMBL7549699 | 0.85 | CCR2 (0.60) | CCR2HRH3ACHECYP1A2CYP2D6 | |
| SCHEMBL7550216 | 0.85 | CCR2 (0.41) | CCR2HRH3AURKAACHEADORA2A | |
| SCHEMBL7554558 | 0.85 | AURKA (0.61) | CCR2HRH3AURKAACHEADORA2A | |
| SCHEMBL7549560 | 0.84 | CCR2 (0.56) | CCR2HRH3AURKAACHEHTR7 | |
| SCHEMBL7554509 | 0.84 | CCR2 (0.56) | CCR2HRH3AURKAACHEADORA2A | |
| SCHEMBL7548839 | 0.81 | CCR2 (0.81) | CCR2HRH3ACHECYP1A2CYP2D6 | |
| SCHEMBL7547688 | 0.80 | CCR2 (0.64) | CCR2ACHEMCHR1 | |
| SCHEMBL7553586 | 0.80 | CCR2 (0.64) | CCR2HRH3ACHEHTR7GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020099054-A1 | 2-phenyl benzimidazole derivatives as MCP-1 antagonists | WARNER-LAMBERT COMPANY (US) | 2002-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020099054-A1 | 2-phenyl benzimidazole derivatives as MCP-1 antagonists | CCR1, CCR2, CCR8 | CCR2 2/4885HRH3 165/4885AURKA 4675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.